|
|
|
RALEIGH, N.C., Nov. 23, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, presented clinical data results for KRN5500, its lead compound for Neuropathic Pain, which achieved...
THE DRUG CANDIDATE GFT505 STATISTICALLY MEETS ALL THE PRIMARY END POINTS OF THE STUDY GFT505-2083 IN PREDIABETIC PATIENTS ? THE STUDY CONFIRMS THE EXCELLENT EFFICACY TO SAFETY RATIO OF GFT505 IN PATIENTS SUFFERING FROM...
NEW YORK, Nov. 19 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that it has sent the following letter to its shareholders, discussing the Company's acquisition, on October 30, 2009, of China...
Rockville firm, Glaxo team up Drug seeks to block nicotine from brain Washington Post Staff Writer Monday, November 23, 2009 Smokers have tried a long list of ways to quit: cold turkey, counseling, gum, patches and more. Nabi...
Posted on: Monday, 23 November 2009, 07:00 CST MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: CEPH) today...
SAN DIEGO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management team that is driving the...
LX1031 represents a first-in-class compound for IBS - First demonstration of new mechanism of action in treatment of IBS Presentation summary will be available at www.lexpharma.com on November 25, 2009 THE WOODLANDS, Texas,...
by: Michael Catalin Vlaicu November 23, 2009 | about: Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation . As of 11/18/09, the biopharmaceutical company announced...
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has...
GENEVA, November 23 /PRNewswire/ -- - China's Research and Development Organization Will Become the Fourth Key R&D Hub for Merck Serono Worldwide - Merck Serono Plans to Invest More Than 150 Million EUR Merck Serono, a division...
